Lenzing Shareholders Face Two Clocks: Rights Deadline and the Profit Test

Lenzing's €300M capital increase is fully underwritten, removing execution risk, but Berenberg's downgrade keeps focus on whether earnings can improve.

Lenzing's capital increase is fully underwritten, which settles one question and leaves another wide open. The €300 million cash call launched roughly two weeks ago carries a subscription price of €8.65 per new share, with a 10:9 ratio — nine new shares for every ten existing ones. That structure removes execution risk from the equation. It does nothing to answer whether the money will be deployed into a business that can earn its cost of capital.

Two dates now frame the mechanics. The last day of rights trading on the Vienna Stock Exchange is scheduled for 14 October, and the subscription period is set to close on 20 October. New shares are expected to start trading on 23 October, subject to the capital increase being entered in the commercial register. None of these milestones speaks to earnings power.

Berenberg's Downgrade Put the Focus on Execution

The analytical case against the equity story arrived about two weeks ago, when Berenberg cut Lenzing from Buy to Hold and slashed its price target from €29.50 to €17.00. Analyst Sebastian Bray anchored the downgrade on a specific gap: higher cotton and viscose prices have not flowed through to Lenzing's results to the extent expected. The upcoming capital increase also featured in his assessment.

That reasoning matters more than the target itself. A €17.00 objective is a snapshot of expectations at a moment in time, not a forecast of where the stock will trade. The underlying observation — that favorable price conditions are not converting into better numbers — is the variable shareholders should track.

At €8.65, the subscription price sits below Friday's close of €10.64. The arithmetic is straightforward; the interpretation is not. A discount to the last traded price says nothing about whether the new shares are cheap in any meaningful sense.

Ownership Shifts Add Noise, Not Signal

Two separate disclosures have reshuffled the register. Goldman Sachs reported on 2 October that its aggregate position had fallen to 3.86%. NN Group, in a filing published Tuesday, disclosed a reduction in its voting rights from 6.27% to 2.54%, with the threshold crossed on 2 October.

Neither filing establishes motive, and neither should be read as a verdict on the capital increase. A smaller stake is not evidence of operational deterioration, just as the B&C Group's commitment to take up its pro-rata share is not proof that subscribing is attractive. Both are facts about who owns what, not about what the company will earn.

The same discipline applies to transactions around the rights themselves. Oberbank acquired subscription rights on Thursday, and management board member Christian Skilich received rights in connection with the cash call. These confirm participation in the process. They do not confirm an improvement in profitability.

The Bull Case Rests on a Single Premise

A constructive view of the rights issue requires one thing to go right: higher cotton and viscose prices must eventually show up in the income statement with more force than they have so far. Should that happen, the central plank of Berenberg's downgrade would weaken, and the capital raise would coincide with a more convincing earnings trajectory.

Under that scenario, the full underwriting and B&C's commitment serve as a financial backstop rather than the investment case itself. The additional capital would be part of a longer-term recovery thesis, not merely a response to subscription terms. Even NN Group's reduced position would not invalidate the argument — an investor's decision and a company's future performance are different things.

The Bear Case Is About Dilution Without Delivery

The opposite outcome is a continuation of what Berenberg described: prices stay favorable, results stay disappointing. In that world, the capital increase is a financing event and nothing more. For existing holders, the expansion of the share count introduces a further consideration — those who do not subscribe in proportion will see their percentage stake diluted, while those who do must commit fresh capital. Neither path resolves the uncertainty about future earnings.

The real risk, then, is not that the transaction fails to close. It is that shareholders inject new money while the anticipated earnings improvement never materializes.

Separating the Calendar From the Thesis

Both the 14 October rights deadline and the 20 October subscription cutoff concern the execution of the capital increase and the options available to rights holders. They are administrative markers. The economic decision extends well beyond them: whether Lenzing can be trusted to convert better pricing into better results. That judgment, not the completion of the paperwork, is what should drive the subscription choice.